Compare DoorDash Inc (DASH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs State Street SPDR S&P Biotech ETF — how do they compare? DoorDash Inc trades at $190.67 (market cap $83.07B), while State Street SPDR S&P Biotech ETF trades at $150.4 (market cap $10.11B). The key difference: DoorDash Inc is far larger — about 8.2× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| DASH | XBI | |
|---|---|---|
Market Cap | $83.07B | $10.11B |
Volume | 3,242,567 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $275.44 | $169.55 |
52-Week Low | $146.60 | $104.99 |
Typical Hold Time | 59 Days | 37 Days |
Enterprise Value | $81.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.24, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $13.72 billion in 2025, and achieved profitability with a net income margin of 6.81%. Recent developments include the launch of AI-powered text ordering and drone delivery expansion, signaling innovation in its core delivery business.
The outlook is positive with a consensus price target of $255.80, though high valuation multiples and mixed quarterly earnings misses pose risks. Investor sentiment is bolstered by analyst optimism, but regulatory scrutiny and competitive pressures remain key concerns for sustained growth.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
